Literature DB >> 25961778

Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.

M Kim1, S-A Yahng2, A Kwon1, J Park1, Y-W Jeon2, J-H Yoon2, S-H Shin2, S-E Lee2, B-S Cho2, K-S Eom2, S Lee2, C-K Min2, H-J Kim2, S-G Cho2, D-W Kim2, J-W Lee2, W-S Min2, S-H Lee3, Y-J Kim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25961778     DOI： 10.1038/bmt.2015.110

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.

Authors:  Thomas Prébet; Sylvain Thepot; Steven D Gore; François Dreyfus; Pierre Fenaux; Norbert Vey
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

2.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

3.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

4.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

5.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome.

Authors:  Y Kita-Sasai; S Horiike; S Misawa; H Kaneko; M Kobayashi; M Nakao; H Nakagawa; H Fujii; M Taniwaki
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

6.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

7.  Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.

Authors:  Eun Mi Je; Nam Jin Yoo; Yoo Jin Kim; Myung Shin Kim; Sug Hyung Lee
Journal:  Int J Cancer       Date:  2013-02-05       Impact factor: 7.396

8.  Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.

Authors:  Seung-Ah Yahng; Jae-Ho Yoon; Seung-Hwan Shin; Sung-Eun Lee; Byung-Sik Cho; Dong-Gun Lee; Ki-Seong Eom; Seok Lee; Chang-Ki Min; Hee-Je Kim; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Tai-Gyu Kim; Chong-Won Park; Yoo-Jin Kim
Journal:  Eur J Haematol       Date:  2013-01-07       Impact factor: 2.997

9.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
View more
  9 in total

1.  Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.

Authors:  S-A Yahng; Y-W Jeon; J-H Yoon; S-H Shin; S-E Lee; Y-S Choi; D-Y Kim; J-H Lee; B-S Cho; K-S Eom; S Lee; C-K Min; H-J Kim; J-W Lee; K-H Lee; W-S Min; J-H Lee; Y-J Kim
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

2.  Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

Authors:  Stefan O Ciurea; Abhishek Chilkulwar; Rima M Saliba; Julianne Chen; Gabriela Rondon; Keyur P Patel; Haitham Khogeer; Abdul R Shah; Brion V Randolph; Jorge M Ramos Perez; Uday Popat; Chitra M Hosing; Qaiser Bashir; Rohtesh Mehta; Gheath Al-Atrash; Jin Im; Issa F Khouri; Partow Kebriaei; Richard E Champlin
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

3.  Genetic Characteristics According to Subgroup of Acute Myeloid Leukemia with Myelodysplasia-Related Changes.

Authors:  Dain Kang; Jin Jung; Silvia Park; Byung-Sik Cho; Hee-Je Kim; Yeojae Kim; Jong-Mi Lee; Hoon Seok Kim; Ari Ahn; Myungshin Kim; Yonggoo Kim
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

4.  Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Authors:  Yaoqing Shen; Cameron J Grisdale; Sumaiya A Islam; Pinaki Bose; Jake Lever; Eric Y Zhao; Natalie Grinshtein; Yussanne Ma; Andrew J Mungall; Richard A Moore; Xueqing Lun; Donna L Senger; Stephen M Robbins; Alice Yijun Wang; Julia L MacIsaac; Michael S Kobor; H Artee Luchman; Samuel Weiss; Jennifer A Chan; Michael D Blough; David R Kaplan; J Gregory Cairncross; Marco A Marra; Steven J M Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-30       Impact factor: 11.205

5.  Consequences of mutant TET2 on clonality and subclonal hierarchy.

Authors:  Cassandra M Hirsch; Aziz Nazha; Kassy Kneen; Mohamed E Abazeed; Manja Meggendorfer; Bartlomiej P Przychodzen; Niroshan Nadarajah; Vera Adema; Yasunobu Nagata; Abhinav Goyal; Hassan Awada; Mohammad Fahad Asad; Valeria Visconte; Yihong Guan; Mikkael A Sekeres; Ryszard Olinski; Babal Kant Jha; Thomas LaFramboise; Tomas Radivoyevitch; Torsten Haferlach; Jaroslaw P Maciejewski
Journal:  Leukemia       Date:  2018-05-24       Impact factor: 12.883

6.  Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis.

Authors:  Yun Lin; Zhijuan Lin; Kun Cheng; Zhihong Fang; Zhifeng Li; Yiming Luo; Bing Xu
Journal:  Oncotarget       Date:  2017-06-27

7.  Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.

Authors:  Xue Zheng; Zhi Zhan; Duolan Naren; Jing Li; Tianyou Yan; Yuping Gong
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

8.  Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.

Authors:  Seung-Ah Yahng; Myungshin Kim; Tae-Min Kim; Young-Woo Jeon; Jae-Ho Yoon; Seung-Hwan Shin; Sung-Eun Lee; Ki-Seong Eom; Seok Lee; Chang-Ki Min; Hee-Je Kim; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Yoo-Jin Kim
Journal:  Oncotarget       Date:  2017-02-14

9.  TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.

Authors:  Hongxia Yao; Mengling Duan; Lie Lin; Congming Wu; Xiangjun Fu; Hua Wang; Li Guo; Wenting Chen; Li Huang; Dan Liu; Ruo Rao; Shuwen Wang; Yipeng Ding
Journal:  Oncotarget       Date:  2017-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.